Long-term outcome in young women with breast cancer: a population-based study

[1]  Adrian V. Lee,et al.  The molecular landscape of premenopausal breast cancer , 2015, Breast Cancer Research.

[2]  K. Czene,et al.  Predictors of Discontinuation of Adjuvant Hormone Therapy in Patients With Breast Cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  A. Schneeweiss,et al.  Outcome after neoadjuvant chemotherapy in young breast cancer patients: a pooled analysis of individual patient data from eight prospectively randomized controlled trials , 2015, Breast Cancer Research and Treatment.

[4]  C. Fan,et al.  Gene expression in “young adult type” breast cancer: a retrospective analysis , 2015, Oncotarget.

[5]  R. Aft,et al.  Abstract P4-14-04: United States breast cancer mortality trends in young women according to race , 2015 .

[6]  G. Di,et al.  Luminal B subtype: A key factor for the worse prognosis of young breast cancer patients in China , 2015, BMC Cancer.

[7]  G. Karen,et al.  Breast cancer in young women: have the prognostic implications of breast cancer subtypes changed over time? , 2014, Breast Cancer Research and Treatment.

[8]  Christos Sotiriou,et al.  Luminal B breast cancer: molecular characterization, clinical management, and future perspectives. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  O. Yersal,et al.  Biological subtypes of breast cancer: Prognostic and therapeutic implications. , 2014, World journal of clinical oncology.

[10]  M. Lai,et al.  Distinct clinicopathological features and prognosis of emerging young-female breast cancer in an East Asian country: a nationwide cancer registry-based study. , 2014, The oncologist.

[11]  Y. Im,et al.  Abstract P4-06-06: Prevalence and clinical outcomes of young breast cancer (YBC) patients according to intrinsic breast cancer subtypes: Single institutional experience in Korea , 2013 .

[12]  C. Perou,et al.  Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  K. Hess,et al.  The prognostic impact of age in patients with triple-negative breast cancer , 2013, Breast Cancer Research and Treatment.

[14]  Caroline Kampf,et al.  Production of Tissue Microarrays, Immunohistochemistry Staining and Digitalization Within the Human Protein Atlas , 2012, Journal of visualized experiments : JoVE.

[15]  C. Sotiriou,et al.  Elucidating Prognosis and Biology of Breast Cancer Arising in Young Women Using Gene Expression Profiling , 2012, Clinical Cancer Research.

[16]  Marc E. Lenburg,et al.  Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657) , 2011, Breast Cancer Research and Treatment.

[17]  Jack Cuzick,et al.  Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. , 2011, Journal of the National Cancer Institute.

[18]  F. Pontén,et al.  The Human Protein Atlas as a proteomic resource for biomarker discovery , 2011, Journal of internal medicine.

[19]  D. Noh,et al.  Prognostic Significance of Young Age (<35 Years) by Subtype Based on ER, PR, and HER2 Status in Breast Cancer: A Nationwide Registry-Based Study , 2011, World Journal of Surgery.

[20]  E. Lundberg,et al.  Towards a knowledge-based Human Protein Atlas , 2010, Nature Biotechnology.

[21]  A. Luini,et al.  Prognosis and adjuvant treatment effects in selected breast cancer subtypes of very young women (<35 years) with operable breast cancer. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[22]  Dawn L Hershman,et al.  Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  E. Winer,et al.  The effect of age on delay in diagnosis and stage of breast cancer. , 2010, The oncologist.

[24]  Päivi Heikkilä,et al.  Subtyping of Breast Cancer by Immunohistochemistry to Investigate a Relationship between Subtype and Short and Long Term Survival: A Collaborative Analysis of Data for 10,159 Cases from 12 Studies , 2010, PLoS medicine.

[25]  D. Dabbs,et al.  Immunohistochemical surrogate markers of breast cancer molecular classes predicts response to neoadjuvant chemotherapy , 2010, Cancer.

[26]  C. Compton,et al.  The American Joint Committee on Cancer: the 7th Edition of the AJCC Cancer Staging Manual and the Future of TNM , 2010, Annals of Surgical Oncology.

[27]  M. A. Chung,et al.  Elevated Breast Cancer Mortality in Women Younger than Age 40 Years Compared with Older Women Is Attributed to Poorer Survival in Early-Stage Disease , 2009 .

[28]  L. Holmberg,et al.  Breast Cancer in Young Women: Poor Survival Despite Intensive Treatment , 2009, PloS one.

[29]  R. Aft,et al.  Patient and tumor characteristics associated with increased mortality in young women (≤40 years) with breast cancer , 2009, Journal of surgical oncology.

[30]  J. Marks,et al.  Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  S. Pocock,et al.  Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies , 2007, BMJ : British Medical Journal.

[32]  M. J. van de Vijver,et al.  Chromogenic in situ hybridisation for the assessment of HER2 status in breast cancer: an international validation ring study , 2007, Breast Cancer Research.

[33]  W. Han,et al.  Poor outcome of hormone receptor-positive breast cancer at very young age is due to tamoxifen resistance: nationwide survival data in Korea--a report from the Korean Breast Cancer Society. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  C. Perou,et al.  The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer Subtypes , 2007, Clinical Cancer Research.

[35]  A. Luini,et al.  Role of endocrine responsiveness and adjuvant therapy in very young women (below 35 years) with operable breast cancer and node negative disease. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[36]  for the Statistics Subcommittee of the NCI—EORTC Worki Diagnostics.  REporting recommendations for tumor MARKer prognostic studies (REMARK) , 2005, Nature Clinical Practice Oncology.

[37]  C. Ko,et al.  Do young breast cancer patients have worse outcomes? , 2003, The Journal of surgical research.

[38]  Jerry Avorn,et al.  Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  A. Luini,et al.  Very young women (<35 years) with operable breast cancer: features of disease at presentation. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[40]  R. Gray,et al.  Adjuvant therapy for very young women with breast cancer: need for tailored treatments. , 2001, Journal of the National Cancer Institute. Monographs.

[41]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[42]  D. Larsimont,et al.  Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples. , 2000, The American journal of pathology.

[43]  R. Gelber,et al.  Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer? , 2000, The Lancet.

[44]  P. Andersen,et al.  Factors influencing the effect of age on prognosis in breast cancer: population based study , 2000, BMJ : British Medical Journal.

[45]  I Persson,et al.  The relation between survival and age at diagnosis in breast cancer. , 1986, The New England journal of medicine.

[46]  N. Mantel.  Evaluation of survival data and two new rank order statistics arising in its consideration. , 1966, Cancer chemotherapy reports.

[47]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[48]  M. Gilcrease.  Tumour biomarker expression relative to age and molecular subtypes of invasive breast cancer , 2013 .

[49]  Anthony Rhodes,et al.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. , 2007, Archives of pathology & laboratory medicine.

[50]  I. Ellis,et al.  Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. , 2002, Histopathology.

[51]  D.,et al.  Regression Models and Life-Tables , 2022 .